What Corvus Pharmaceuticals, Inc. told the SEC could break it.

Corvus's entire value depends on regulatory approvals that are never guaranteed — the FDA and comparable foreign authorities (including in China) can delay, limit or deny approval for many reasons, and there is specific uncertainty over whether the FDA will accept data from clinical trials its 49.7%-owned affiliate Angel Pharmaceuticals conducts in China as a basis for U.S. approval; if approved and commercialized, products would also face Inflation Reduction Act Medicare price-negotiation and rebate pressures and broad healthcare-fraud/reimbursement laws.

“The FDA or comparable foreign regulatory authorities, including in China, can delay, limit or deny approval of a product candidate for many reasons”

Corvus has incurred operating losses since its 2014 inception with a $412.3 million accumulated deficit and no product revenue (none of its candidates are approved); its $56.8 million of cash/marketable securities at year-end 2025 plus a January 2026 follow-on (~$189.4M net) are expected to fund operations only into the second quarter of 2028 and not through completion of its trials or commercialization, so it will need substantial additional capital and faces dilution/financing risk.

“our cash, cash equivalents and marketable securities of $56.8 million as of December 31, 2025 and the proceeds from our recent financing, we expect that our existing capital resources will be sufficient to fund our operations into the second quarter of 2028.”

Although Corvus can internally produce small quantities of its product candidates for short preclinical studies, it relies and expects to continue to rely on a number of third-party contract manufacturers to produce sufficient quantities for lengthier preclinical and clinical trials and any future commercialization; dependence on these CMOs (subject to cGMP and FDA pre-approval inspection) creates supply, quality and capacity risk it cannot fully control.

“we currently rely, and expect to continue to rely, on a number of contract manufacturers to produce sufficient quantities of our product candidates for use in more lengthy preclinical development and clinical trials”